STING Licensing of Type I Dendritic Cells Potentiates Antitumor Immunity

Using a polymeric STING-activating nanoparticle with a shock-and-lock dual activation mechanism, investigators showed that conventional type 1 dendritic cells were essential for STING-mediated rejection of multiple established and metastatic murine tumors.